Moleculin Biotech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
64.1%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$2.94next fiscal year
Monitoring Framework
Key Performance Indicators
MIRACLE Trial Subject Enrollment Quarterly45.0Target: 90 (Part A Target)
Cash and Cash Equivalents Quarterly10.3MTarget: Secure additional financing to extend cash runway beyond Q3 2026
Annamycin Treated Subjects Reviewed for Cardiotoxicity Annually90.0Target: Continuous safety monitoring
Watch Items
- MIRACLE Trial Part A 45-Subject UnblindingTrigger: Mid-2026Action: Evaluate efficacy (CRc rate) and safety data to confirm therapeutic signal.
- Going Concern Risk and Capital RunwayTrigger: Q3 2026 cash depletionAction: Secure approximately $25 million in additional financing to extend runway into Q1 2027.
- MIRACLE Trial Part A 90-Subject Recruitment and UnblindingTrigger: Q3 2026Action: Complete Part A recruitment and prepare for transition to Part B in 2H 2026.
Research as of 20 Jun 2026